Skip to Main Content

Thrombotic Microangiopathy

The role of caplacizumab in the treatment of thrombotic thrombocytopenic purpura remains controversial given its high cost and limited benefit, despite its inclusion in 2020 guidelines.

Careful monitoring of the ADAMTS-13 activity and inhibitor status and use of rituximab can prevent dangerous relapses.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.